Company / Cost of Revenue
CHINA PHARMA HOLDINGS, INC. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$4.3M
FY2025
5-year range
$4.3M / $8.9M
FY2021-FY2025
Trend
-41.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $7M to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of -14.7%.
Improved from $7M to $4M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -20.8%
- 5-Year CAGR
- -14.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -14.7%, indicating a declining trend.
- In FY2025, cost of revenue decreased 41.4% year-over-year.
- Peak cost of revenue was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.3M | -41.4% |
| FY2024 | $7.3M | +0.0% |
| FY2023 | $7.3M | -15.2% |
| FY2022 | $8.6M | -3.5% |
| FY2021 | $8.9M | -5.6% |
| FY2020 | $9.4M | -8.8% |
| FY2019 | $10.4M | -3.6% |
| FY2018 | $10.7M | -13.0% |
| FY2017 | $12.4M | -21.7% |
| FY2016 | $15.8M | -8.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026